Key result
Daily Ecklonia stolonifera extract improves LVFS versus vehicle in post-MI rats.
Why the study?
Ecklonia stolonifera Okamura extract has known bioactive effects, but its effects on cardiovascular disease had not yet been investigated.
Does Ecklonia stolonifera Okamura extract improve left ventricular systolic dysfunction and suppress hypertrophic responses in myocardial infarction-induced heart failure models?
RCT (n=29)
randomly assigned
Does Ecklonia stolonifera Okamura extract improve left ventricular systolic dysfunction and suppress hypertrophic responses in myocardial infarction-induced heart failure models?
Ecklonia stolonifera Okamura extract suppresses myocardial infarction-induced left ventricular systolic dysfunction and cardiomyocyte hypertrophy by inhibiting p300-HAT activity in rat models.
Hypothesis-generating for Ecklonia extract in post-MI LV dysfunction; leaves open translation to human systolic heart failure.
Ecklonia stolonifera Okamura extract (ESE) has been reported to have various bioactive effects, but its effects on cardiovascular disease have not yet been investigated. First, primary neonatal rat cultured cardiomyocytes were treated with ESE and stimulated with phenylephrine (PE) for 48 h. ESE (1000 µg/mL) significantly suppressed PE-induced cardiomyocyte hypertrophy, hypertrophy-related gene transcription, and the acetylation of histone H3K9. An in vitro p300-HAT assay indicated that ESE directly inhibited p300-HAT activity. Next, one week after myocardial infarction (MI) surgery, rats (left ventricular fractional shortening (LVFS) < 40%) were randomly assigned to three groups: vehicle (saline, n = 9), ESE (0.3 g/kg, n = 10), or ESE (1 g/kg, n = 10). Daily oral administration was carried out for 8 weeks. After treatment, LVFS was significantly higher in the ESE (1 g/kg) group than in the vehicle group. The ESE treatments also significantly suppressed MI-induced increases in myocardial cell diameter, perivascular fibrosis, hypertrophy- and fibrosis-related gene transcription, and the acetylation of histone H3K9. These results suggest that ESE suppressed both hypertrophic responses in cardiomyocytes and the development of heart failure in rats by inhibiting p300-HAT activity. Thus, this dietary extract is a potential novel therapeutic strategy for heart failure in humans.
No takes yet. Share an insight, caveat, or question.
Katagiri et al. (2022) conducted an RCT in Myocardial Infarction-Induced Left Ventricular Systolic Dysfunction (n=29). Ecklonia stolonifera Okamura extract vs. Vehicle (saline) was evaluated on Left ventricular fractional shortening (LVFS). Daily oral administration of Ecklonia stolonifera Okamura extract (1 g/kg) significantly improved left ventricular fractional shortening compared to vehicle in rats post-myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: